Lung Cancer Management最新文献

{"title":"Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.","authors":"Nick Jovanoski,&nbsp;Kathleen Bowes,&nbsp;Audrey Brown,&nbsp;Rossella Belleli,&nbsp;Danilo Di Maio,&nbsp;Shkun Chadda,&nbsp;Seye Abogunrin","doi":"10.2217/lmt-2023-0003","DOIUrl":"https://doi.org/10.2217/lmt-2023-0003","url":null,"abstract":"<p><strong>Aim: </strong>Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients.</p><p><strong>Methods: </strong>Review of long-term survival and quality-of-life after curative treatment in eNSCLC patients in observational studies.</p><p><strong>Results: </strong>Disease-free proportion decreased in stage III vs stage I patients. Recurrence-free proportion decreased with age and disease stage. Advanced stage and vascular invasion increased risk of late recurrence. Conditional 5-year relative survival rates did not exceed 87%, indicating higher mortality in eNSCLC survivors. Lower conditional survival rates and relative survival rates were associated with older age and advanced disease. Survivors of eNSCLC had poorer physical quality-of-life.</p><p><strong>Conclusion: </strong>Despite curative-intent therapy, survivors of eNSCLC still face significant risks of recurrence, excess mortality, and diminished quality-of-life.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/bb/lmt-12-60.PMC10485735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10223049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alectinib for treating patients with metastatic <i>ALK</i>-positive NSCLC: systematic review and network metanalysis.","authors":"Daniel Samacá-Samacá,&nbsp;Laura Prieto-Pinto,&nbsp;Andrés Yepes Peréz,&nbsp;Carolina Valderrama,&nbsp;Fabián Hernández","doi":"10.2217/lmt-2022-0018","DOIUrl":"https://doi.org/10.2217/lmt-2022-0018","url":null,"abstract":"<p><strong>Aim: </strong>To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced <i>ALK</i>-positive NSCLC.</p><p><strong>Methods: </strong>A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted.</p><p><strong>Results: </strong>13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibitors. Alectinib showed a good safety profile compared with the other ALK inhibitors.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/ba/lmt-12-59.PMC10242442.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9955054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.","authors":"Christopher Cronin,&nbsp;Shahid Iqbal,&nbsp;Abdul R Farooq,&nbsp;Pauline O'Dea,&nbsp;Louise Burke,&nbsp;Seamus O'Reilly,&nbsp;Deirdre O'Mahony,&nbsp;Derek G Power,&nbsp;Richard M Bambury,&nbsp;Dearbhaile C Collins","doi":"10.2217/lmt-2022-0014","DOIUrl":"https://doi.org/10.2217/lmt-2022-0014","url":null,"abstract":"<p><strong>Aim: </strong>Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.</p><p><strong>Methods: </strong>We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.</p><p><strong>Results: </strong>62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.</p><p><strong>Conclusion: </strong>High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/4b/lmt-12-58.PMC10241113.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9591368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing physician education to increase lung cancer screening uptake.","authors":"Coral Olazagasti,&nbsp;Nagashree Seetharamu,&nbsp;Nina Kohn,&nbsp;David Steiger","doi":"10.2217/lmt-2022-0008","DOIUrl":"https://doi.org/10.2217/lmt-2022-0008","url":null,"abstract":"<p><strong>Aim: </strong>Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. The US Preventive Services Task Force and National Comprehensive Cancer Network recommend annual low-dose computed tomography (LDCT) for eligible adults. We conducted a study to assess physician LDCT referral patterns.</p><p><strong>Methods: </strong>The study was divided into a pre-, intervention, and post-intervention periods. The intervention was a LC screening educational series. We evaluated rates of LDCT screening referrals during pre- and post-intervention periods.</p><p><strong>Results: </strong>In the pre-intervention period, 75 patients fulfilled US Preventive Services Task Force and/or National Comprehensive Cancer Network criteria and 27% underwent LDCT. In the post-intervention period, 135 patients fulfilled either screening criteria of whom 61.5% underwent LDCT.</p><p><strong>Conclusion: </strong>In our study, educational lectures improved compliance significantly and should be used as tool for primary care providers to effectively increase LDCT screening referrals.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/9c/lmt-11-55.PMC10135441.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9392586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy.","authors":"Shinnosuke Takemoto,&nbsp;Mutsumi Ozasa,&nbsp;Remi Mizuta,&nbsp;Ryuta Tagawa,&nbsp;Sawana Ono,&nbsp;Noritaka Honda,&nbsp;Takayuki Suyama,&nbsp;Yasuhiro Umeyama,&nbsp;Yosuke Dotsu,&nbsp;Hiroshi Gyotoku,&nbsp;Hiroyuki Yamaguchi,&nbsp;Kazuko Yamamoto,&nbsp;Noriho Sakamoto,&nbsp;Yasushi Obase,&nbsp;Minoru Fukuda,&nbsp;Hiroshi Mukae","doi":"10.2217/lmt-2022-0001","DOIUrl":"https://doi.org/10.2217/lmt-2022-0001","url":null,"abstract":"<p><strong>Background: </strong>The lung cancer biopsy specimens obtained by endobronchial ultrasound-guide sheath (EBUS-GS) trans lung biopsy occasionally do not contain cancer cells. It is a problem that there is a possibility that they may not contain cancer cells.</p><p><strong>Aim of the study: </strong>To investigate the proportion of biopsy specimens containing cancer cells in total biopsy specimens.</p><p><strong>Materials & methods: </strong>Patients with lung cancer diagnosed by EBUS-GS were selected. The primary end point was the proportion of specimens containing tumors in the total specimens obtained by EBUS-GS.</p><p><strong>Results: </strong>Twenty-six patients were investigated. The percentage of specimens containing cancer cells in the total specimens was 79.0%.</p><p><strong>Conclusion: </strong>The proportion of biopsy specimens containing cancer cell to all biopsy specimens by EBUS-GS was high, but not 100%.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/50/lmt-11-57.PMC10241111.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9591410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment considerations for patients with advanced squamous cell carcinoma of the lung: a plain language summary.","authors":"Edgardo S Santos,&nbsp;Estelamari Rodriguez","doi":"10.2217/lmt-2022-0017","DOIUrl":"https://doi.org/10.2217/lmt-2022-0017","url":null,"abstract":"<p><strong>What is this article about?: </strong>This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung.</p><p><strong>What is scc of the lung?: </strong>SCC of the lung is a type of non-small-cell lung cancer (NSCLC for short) that is usually linked with smoking. It can be difficult to treat because it is often diagnosed after it has spread to other parts of the body.</p><p><strong>What first-line treatment options are available for people with scc of the lung?: </strong>Most patients receive a combination of chemotherapy and immunotherapy as their first-line treatment (the first treatment they receive after their diagnosis). Immunotherapy drugs have improved how long people with SCC of the lung can live for. However, for most patients, they eventually stop working. At this point, other second-line treatments are considered, meaning treatments patients receive after their first-line treatment is stopped due to side effects or because it no longer works.</p><p><strong>What second-line treatment options are available to people with scc of the lung?: </strong>Immunotherapy drugs were originally developed as second-line options after chemotherapy. However, immunotherapy drugs are now used with chemotherapies as first-line treatments. This has left a gap for second-line treatment options. There are some drugs available for second-line treatment, such as afatinib, which comes as a tablet, and docetaxel with or without ramucirumab, which is given as an infusion. Other potential treatments are being developed.</p><p><strong>What emerging treatment options are being developed?: </strong>Some early clinical trials of potential treatments have shown promise, but more results are needed. Research into the genetic mutations linked with the development of SCC of the lung is also ongoing. It is hoped that this will help identify patients who might benefit from specific treatments.</p><p><strong>Who should read this article?: </strong>People with SCC of the lung and their caregivers, patient advocates, and healthcare professionals, including those who are helping people learn about scientific discoveries and potential new therapeutic strategies.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/84/lmt-11-56.PMC10241114.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9589951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC","authors":"A. Kulkarni, N. Fujioka, Lucia Reinhardt, Manish R. Patel, R. Kratzke","doi":"10.2217/lmt-2021-0001","DOIUrl":"https://doi.org/10.2217/lmt-2021-0001","url":null,"abstract":"We present a patient with metastatic NSCLC harboring a compound EGFR mutation with co-occurring G719A and T790M mutation. T790M mutation was treatment emergent mutation when patient was on early generation tyrosine kinase inhibitors. Initial Guardant 360 showed that G719A was the dominant clone. Following, osimertinib, the patient had only a radiographic disease stabilization and then developed both clinical and radiographic progression. On progression, T790M was undetectable but G719A continued to be the dominant clone. Subsequent administration of afatinib led to a clinical and radiological response. To our knowledge, this is the first case report describing co-occurrence of EGFR G719A and T790M mutations and the clonal evolution during treatment with anti-EGFR therapies.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42910291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study.","authors":"Belen Rubio-Viqueira,&nbsp;Margarita Majem Tarruella,&nbsp;Martín Lázaro,&nbsp;Sergio Vázquez Estévez,&nbsp;Juan Felipe Córdoba-Ortega,&nbsp;Inmaculada Maestu Maiques,&nbsp;Jorge García González,&nbsp;Ana Blasco Cordellat,&nbsp;Javier Valdivia-Bautista,&nbsp;Carmen González Arenas,&nbsp;Jose Miguel Sánchez Torres","doi":"10.2217/lmt-2021-0008","DOIUrl":"https://doi.org/10.2217/lmt-2021-0008","url":null,"abstract":"<p><strong>Aim: </strong>To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain.</p><p><strong>Methods: </strong>Multicenter, retrospective study.</p><p><strong>Results: </strong>Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1.</p><p><strong>Conclusion: </strong>PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/81/lmt-10-53.PMC8656292.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enabling patients in effective self-management of breathlessness in lung cancer: the neglected pillar of personalized medicine.","authors":"Doris Howell","doi":"10.2217/lmt-2020-0017","DOIUrl":"10.2217/lmt-2020-0017","url":null,"abstract":"<p><p>Globally, engagement of patients in the self management of disease and symptom problems has become a health policy priority to improve health outcomes in cancer. Unfortunately, little attention has been focused on the provision of self-management support (SMS)in cancer and specifically for complex cancer symptoms such as breathlessness. Current management of breathlessness, which includes treatment of underlying disease, pharmacological agents to address comorbidities and opiates and anxiolytics to change perception and reduce the sense of breathing effort, is inadequate. In this perspective paper, we review the rationale and evidence for a structured, multicomponent SMS program in breathlessness including four components: breathing retraining, enhancing positive coping skills, optimizing exertional capacity and reducing symptom burden and health risks. The integration of SMS in routine lung cancer care is essential to improve breathlessness, reduce psychological distress, suffering and improve quality of life.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/2d/lmt-10-52.PMC8656340.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data.","authors":"Virginia Calvo,&nbsp;Marta Andrés Fernández,&nbsp;Ana Collazo-Lorduy,&nbsp;Fernando Franco,&nbsp;Beatriz Núñez,&nbsp;Mariano Provencio","doi":"10.2217/lmt-2021-0003","DOIUrl":"https://doi.org/10.2217/lmt-2021-0003","url":null,"abstract":"<p><strong>Aim: </strong>Immune checkpoint inhibitors (ICIs) are a cornerstone in cancer treatment but they can induce immune-related adverse events (irAEs). Furthermore, patients with pre-existing autoimmune and/or inflammatory disease (AID) have been excluded from clinical trials. The objective of this study is to evaluate the efficacy and safety of ICIs in patients with cancer and AID.</p><p><strong>Materials & methods: </strong>This is an observational, retrospective study carried out at the Medical Oncology Department of Hospital Universitario Puerta de Hierro, Majadahonda, Madrid between January 2016 and December 2018.</p><p><strong>Results: </strong>A total of 202 cancer patients treated with ICIs were included, 15 (7, 4%) of them had pre-existing autoimmune diseases. The most frequent pre-existing AID were thyroid diseases (33.3%): autoimmune hypothyroidism, Graves-Basedow disease and Hashimoto's thyroiditis. Three patients had psoriasis, two antinuclear antiboides + polyarthritis, one rheumatoid arthritis, another latent autoimmune diabetes in adults, another systemic lupus erythematosus and the last one, a polymyalgia rheumatica. In this series, the majority of patients (73.33%) did not experience any flare up of their autoimmune disease. In patients who had AID flare up, this was treated with corticosteroids. The most frequent cause of immunotherapy discontinuation was tumor progression (40%). A total of 20% of patients had to discontinue immunotherapy due to toxicity.</p><p><strong>Conclusion: </strong>In our series, AID flare ups or irAEs in patients with pre-existing AID who receive immunotherapy are not very common and can often be controlled without interrupting treatment. Prospective studies are needed to establish the incidence of irAEs in patients with pre-existing autoimmune conditions, evaluate risk-benefit and elaborate management clinical guidelines in this population.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/a3/lmt-10-51.PMC8656306.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}